Get the Stockscreener App
0.6374
3.75%
-0.0327
Reshape Lifesciences Inc stock is traded at $0.6374, with a volume of 13,666.
It is down -3.75% in the last 24 hours and down -75.00% over the past month.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.
See More
Previous Close:
$0.6701
Open:
$0.64
24h Volume:
13,666
Relative Volume:
0.01
Market Cap:
$2.10M
Revenue:
$9.81M
Net Income/Loss:
$-26.16M
P/E Ratio:
-0.0164
EPS:
-38.77
Net Cash Flow:
$-17.45M
1W Performance:
-33.28%
1M Performance:
-75.00%
6M Performance:
-93.48%
1Y Performance:
-93.74%
1-Day Range:
$0.631
$0.645
1-Week Range:
$0.626
$0.9508
52-Week Range:
$0.626
$29.00
Reshape Lifesciences Inc Stock (RSLS) Company Profile
Name
Reshape Lifesciences Inc
Sector
Industry
Phone
949-429-6680
Address
1001 CALLE AMANECER, SAN CLEMENTE
Compare RSLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RSLS
Reshape Lifesciences Inc
|
0.6374 | 2.10M | 9.81M | -26.16M | -17.45M | -38.77 |
|
ABT
Abbott Laboratories
|
126.56 | 225.27B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.81 | 140.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
364.39 | 138.77B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
92.56 | 118.39B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
68.42 | 39.95B | 5.72B | 4.17B | 259.90M | 6.97 |
Reshape Lifesciences Inc Stock (RSLS) Latest News
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week - MSN
First national perception survey of Food is Medicine programs shows strong public support - EurekAlert
Ratio Analysis: Unpacking ReShape Lifesciences Inc (RSLS)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Grow - Asianet Newsable
ReShape Lifesciences® Receives Notice of Allowance for U.S. - GlobeNewswire
ReShape Lifesciences Patents Breakthrough Diabetes Neuromodulation System - StockTitan
ReShape Lifesciences, Inc. to Host Earnings Call - ACCESS Newswire
RSLS stock touches 52-week low at $0.87 amid market challenges - Investing.com Canada
RSLS stock touches 52-week low at $0.87 amid market challenges By Investing.com - Investing.com South Africa
Global Synthetic Biosensors Market Size to Hit USD 49.87 Billion by 2032 -Coherent Market Insights - openPR
Minimally Invasive Bariatric Surgery Equipment Market Accelerating Digital Transformation for a Smarter Future - ExpressVartha
RSLS Stock Touches 52-Week Low at $0.99 Amid Market Challenges - Investing.com Canada
RSLS Stock Touches 52-Week Low at $0.99 Amid Market Challenges By Investing.com - Investing.com South Africa
Pre-market Movers: BTAI, VRPX, DCGO, NBY... - RTTNews
Icahn Enterprises Earnings: What To Look For From IEP - The Globe and Mail
Corcept (CORT) Q4 Earnings Report Preview: What To Look For - The Globe and Mail
Volatus Aerospace and Ondas Holdings Forge Strategic Partnership to Elevate Border Surveillance with Advanced Drone Technologies - The Manila Times
ReShape Lifesciences® Signs Distribution Agreement in - GlobeNewswire
Can ReShape's New Canadian Partnership Transform Its Weight Loss Device Sales? - StockTitan
Liverpool City Region orders 58 next-generation Enviro400EV zero-emission double deckers from NFI subsidiary Alexander Dennis - The Globe and Mail
Why Global Blue Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - NewsBreak
“Technology Stocks to Watch: CSDX, LYT, SINT, TRNR, RSLS, CYCU, TRUG Market Momentum Building” - The Globe and Mail
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.02% - Investing.com
United States shares higher at close of trade; Dow Jones Industrial Average up 0.02% - Investing.com India
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
ReShape Lifesciences prices $6M public offering - MSN
Why GCL Global Holdings Shares Are Trading Higher By Around 107%; Here Are 20 Stocks Moving Premarket - Benzinga India
ReShape Lifesciences Raises Fresh Capital: $6M Strategic Financing Deal Unveiled - StockTitan
Reshape Lifesciences Says Pricing Of Upsized $6.0 Million Public Offering -February 15, 2025 at 11:18 pm EST - Marketscreener.com
ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering - Yahoo Finance
ReShape Lifesciences® Prices Public Offering of 2,575,107 Units at $2.33 Each - Nasdaq
RSLS stock touches 52-week low at $2.57 amid market challenges - Investing.com Nigeria
RSLS stock touches 52-week low at $2.57 amid market challenges By Investing.com - Investing.com South Africa
ReShape Lifesciences secures key diabetes treatment patent - MSN
Vagus Nerve Stimulators Market Witness Growth: Booming Demand, - openPR
Key Trend Revolutionizing the Bariatric Surgery Devices Market in 2025: Olympus Fully Launches Next-Level S... - WhaTech
Synthetic Biosensors Market: Trends, Applications & Growth - openPR
CPI, Powell Testimony and Other Can't Miss Items this Week - The Globe and Mail
Why Amazon Could Be the Best Big Tech Investment of Q1 - The Globe and Mail
AI and Automation reshape revenue management in the Life Sciences industry - ETHealthWorld
Emera Incorporated Announces Results of Series F First Preferred Share Conversion - The Globe and Mail
Accuray (ARAY) Stock Surges Amidst Market Activity - GuruFocus.com
Earnings To Watch: e.l.f. Beauty (ELF) Reports Q4 Results Tomorrow - The Globe and Mail
ReShape Lifesciences receives international patent in Israel for its proprietary diabetes neuromodulation technology; shares rise - MSN
ReShape Lifesciences® Granted Key International Patent in - GlobeNewswire
Groundbreaking Diabetes Tech Patent Win: ReShape's Neural Solution Could Eliminate Daily Medications - StockTitan
Reshape Lifesciences Inc Stock (RSLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.40%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):